David Zaccardelli - 05 Aug 2021 Form 4 Insider Report for Verona Pharma plc (VRNA)

Reporting relationship: President and CEO, Director
Issuer ticker: VRNA
Reported as of: 05 Aug 2021
Net transaction value: -$13,284
SEC form: 4
Accepted by SEC: 09 Aug 2021, 20:58:33 UTC
Prior SEC filing: 04 Aug 2021
Next SEC filing: 03 Nov 2021
Source filing: View source filing
Reporting owner signature: /s/ Claire Poll, Attorney-in-fact for David Zaccardelli

Key filing fact

David Zaccardelli filed Form 4 for Verona Pharma plc (VRNA) on 09 Aug 2021.

Key facts

This page summarizes David Zaccardelli's Form 4 filing for Verona Pharma plc (VRNA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Aug 2021, 20:58.

Change

Previous filing in this sequence was filed on 04 Aug 2021.
Current net transaction value: -$13,284.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRNA transaction

Ordinary Shares

Sale

Transaction value: $13,284
Shares: -17,656
Change %: -0.1%
Price: $0.7524^*
Shares after: 17,352,256
Date: 03 Aug 2021
Ownership: Direct
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Footnote F2

The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units.

Footnote F3

The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.7338 to $0.7813. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3.

Footnote F4

Consists of (i) 11,823,712 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 1,477,964 ADSs); and (ii) 5,528,544 Ordinary Shares underlying 691,068 ADSs.